RCM
ITCI

Raleigh Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Raleigh Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-107
Closed -$7.66K – 1200
2023
Q4 		$7.66K Buy
107
+4
+4% +$230 ﹤0.01% 655
2023
Q3 		$5.37K Buy
103
+42
+69% +$2.45K ﹤0.01% 679
2023
Q2 		$3.87K Buy
61
+20
+49% +$1.25K ﹤0.01% 687
2023
Q1 		$2.22K Buy
41
+9
+28% +$435 ﹤0.01% 763
2022
Q4 		$1.69K Buy
32
+16
+100% +$802 ﹤0.01% 698
2022
Q3 		$1K Buy
+16
New +$836 ﹤0.01% 791

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Raleigh Capital Management's ITCI Position: Q1 2024 in Review

Raleigh Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2024, closing a stake of 107 shares — an estimated $7.66K sold.

Raleigh Capital Management first reported a position in ITCI in Q3 2022 and held it in 6 quarters. The position peaked at $7.66K in Q4 2023. 346 funds tracked by Wall St. Rank hold ITCI as of Q1 2024.

  • Raleigh Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2024 after selling out during the quarter.
  • Raleigh Capital Management sold 107 Intra-Cellular Therapies Inc. shares in Q1 2024, an estimated $7.66K.
  • Raleigh Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2022 and held it in 6 quarters.
  • Raleigh Capital Management's Intra-Cellular Therapies Inc. position peaked at $7.66K in Q4 2023.
  • 346 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2024.

Based on Raleigh Capital Management's 13F filing for Q1 2024, filed 13 May 2024.